Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its patented Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to improve antitumor activity. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
September 27, 2023
Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer